Contact FreedomWorks

400 North Capitol Street, NW
Suite 765
Washington, DC 20001

  • Toll Free 1.888.564.6273
  • Local 202.783.3870

Start Your

Personalized

Campaign Now!

Get a custom image featuring your name and photo — share it on your social networks, tweet it at key policy makers, and more!

All the Latest

    Everything
  • Blog
  • Events
  • Press
  • Key Votes
  • Podcasts
  • Videos
  • Tweets
  • Photos

In Action

$23,700,000,000,000!
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

$23,700,000,000,000!

That’s 11 zeros for those not counting.  $23.7 trillion dollars – let’s take a moment of silence….   This astronomical number is the total liability that the government has racked up in its series of bailouts of the financial system, according to the Special Inspector General assigned to the Troubled Asset Relief Program (SIGTARP).  Neil Bartofsky is heading up the investigation into how the TARP funds are being used, as well as how the Treasury Department plans to increase transparency within the program.In short:  “Don’t ask, don’t tell,” is the Treasury’s policy.  Bartofsky, in testimony given before the House Oversight and Government Reform Committee meeting today focused on the lack of transparency which leaves the taxpayers unaware of how their investments in the federal government have fared.  The latest Quarterly Report shows the government liability from bailing out the financial services industry totaling $23.7 trillion.  Most people are aware of the $800 billion in TARP funds that are on the line, but as SIGTARP emphasized, that is only a collection of 12 recent government programs invested.  There are 50 other programs already in place that also need to be included in assessing the risk involved, forming the $23.7 trillion total.

07/21/2009
Health Care Petitions Delivered to Capitol Hill
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

Health Care Petitions Delivered to Capitol Hill

Over the 4th of July, Freedomworks volunteers collected hundreds of signatures on petitions opposing socialized medicine at Tea Parties and other events across the country. Last week, FreedomWorks interns delivered those petitions to the appropriate members of Congress. Below are photos of some of those deliveries and contact information for each office. Thanks so much to those patriots who signed and sent in petitions!

07/21/2009
FreedomWorks Leads Grassroots Fight Against ObamaCare
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Press Release

FreedomWorks Leads Grassroots Fight Against ObamaCare

Click here to download the full, .pdf version which includes pictrues!

07/21/2009
Obama's Blue State Betrayal
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

Obama's Blue State Betrayal

A recent report from the non-partisan Tax Foundation shows who will bear the funding burden for the federal government’s health care take over, and proves it’s never too early to say “I told you so.” Nine of the top ten states that will pay the highest income taxes under a “surtax” plan currently being considered in the Democrat-dominated House of Representatives went for Barack Obama last fall. By an average of 25 percent.

07/21/2009
Senators Won't Enroll in Public Option
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

Senators Won't Enroll in Public Option

One of the big points we hear from the grassroots again and again is "If this public plan is so good, will Congress enroll?"  The answer is, of course not.  That's the give-away.  The new public option will be good enough for everyone else, but our elected officials will keep their own cushy plan.

07/20/2009
Missed Opportunity for at least Some Competition-based Health Care Reform
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

Missed Opportunity for at least Some Competition-based Health Care Reform

While the larger debate over liberals' proposed hostile government takeover of America's medical system continues to rage, an opportunity was recently missed to inject some competition in one important area: the life-saving biologic drug market.The Senate HELP committee passed legislation last week that would prevent generic companies from entering the market to compete with brand providers.  These "biogenerics" would provide downward pressure on prices for drugs like Insulin and Avastin (a colon cancer medicine), but not if Congress continues to allow roadblocks to competition.

07/20/2009
On Second Thought, Maybe the U.S. Should Be More Like Europe
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

On Second Thought, Maybe the U.S. Should Be More Like Europe

The Wall Street Journal reports this morning that the European Union and the United States have again chosen different paths regarding free trade, this time with South Korea. However, for once it’s old Europe that wants to boost economic output by lowering barriers. Meanwhile, in the formerly free market U.S., a Congress beholden to Big Labor throws up roadblocks.

07/20/2009
Congressman Jared Polis (D-CO) makes an impression on health care
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

Congressman Jared Polis (D-CO) makes an impression on health care

You have to hand it to Jared Polis: For a freshman Congressman to be quoted in the the NY Times and the Wall Street Journal within 24 hours (and not for some misdeed) is an achievement.

07/20/2009
Oppose Restrictions to Biogeneric Drugs
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Press Release

Oppose Restrictions to Biogeneric Drugs

July 16, 2009Members of the 111th CongressU.S. House of RepresentativesWashington, D.C. 20515Dear Representative,FreedomWorks, a grassroots organization with more than 750,000 members nationwide, is actively engaged in the current debate over health care reform and has been a strong advocate of market-based reforms that would expand consumer choice and competition in the health care sector.  Independent of the larger debate over the direction of health care reform in America, however, I would like to alert you to a potentially dangerous amendment that is being offered to H.R. 3200, American’s Health Choices Act of 2009 by Rep. Eshoo that would severely restrict the emerging market for biogeneric drugs.With the rising cost of pharmaceutical drugs and healthcare, it is increasingly important to encourage competition in the market for life saving therapies.  Biologics show great promise and have been used to produce insulin, human growth hormone, and other important therapies.  Globally, the market for these drugs has increased to more than $60 billion.  To expand this market and increase access to these life-saving drugs, it is important that the Food and Drug Administration has a regulatory pathway to approve biogenerics, or biologic follow-ons.  Much like generics, biogenerics hold the promise of new competiton and expanded consumer choice in new therapies to treat a variety of conditions, from AIDS to Alzheimer’s, to several different cancers.Currently, the FDA has limited authority to approve biogenerics.  Many pharmaceutical companies claim that biologics are too complex to be produced as generics.  This is not true; there are a number of pharmaceutical companies—brand name and generic—that have the capability and desire to enter the market for biologics with expiring patents.  One biogeneric has already been approved by the FDA, and the agency has stated that it believes it is possible to establish an abbreviated approval process for these drugs that allows manufacturers to establish their bioequivalence.  Already, the European Union and Australia have established procedures to approve biogenerics.  As an important component of health care reform,  Congress should move forward with legislation to ensure all Americans enjoy access to the latest therapeutic drugs at the most affordable prices.  Unfortunately, the Eshoo Amendment includes a 12-year exclusivity period that will do little to promote the competition necessary to expand consumer choice and check rising health care costs. A market approach is the correct solution to getting less expensive therapies to patients, as it also encourages the development of new and desperately needed medicines.  For these reasons,  I urge you to vote “no” on the Eshoo Amendment.  FreedomWorks will continue to follow the health care reform debate closely, advocating market-based reforms that expand patient choice and improve access to life-saving therapies.Sincerely,Matt KibbePresident and CEO

07/16/2009
A Sign of Things to Come?
null
http://d7.freedomworks.org.s3.amazonaws.com/styles/thumbnail/s3/te_social_media_share/fw_default_0.jpg?itok=mX_C44GW
Blog

A Sign of Things to Come?

Remember when Massachusetts overhauled its health care system?It wasn't too long ago. Two thousand and six (AD) to be precise.Well, the utopian project is now forcing its passengers to brace for impact as it experiences potentially terminal turbulence due to out of control costs associated with the massive entitlement program.

07/16/2009

Pages